Status:
COMPLETED
Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Massachusetts General Hospital
Evidera
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
Detailed Description
AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of participants throughout their part...
Eligibility Criteria
Inclusion
- \>18 years of age at the time of enrollment
- Clinically confirmed diagnosis of asthma
- Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
- Able to understand and speak English sufficiently to be able to use the AMAZE™ patient app
- Willingness to participate in a telephone interview and be audio-recorded
- Consenting to participate in the study
Exclusion
- Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma
- Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™.
Key Trial Info
Start Date :
April 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2021
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04868500
Start Date
April 27 2021
End Date
November 30 2021
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Boston, Massachusetts, United States, 02114